Japanese Drugmakers Tap China’s Rising R&D Strength for Growth

Takeda chief says China’s drug development capabilities are approaching US standards

An Astellas Pharma office in Beijing. The company is preparing to open a new R&D facility in a Beijing industrial park. (Astellas Pharma)

TOKYO — Japanese pharmaceutical companies are increasing investment in China, the world’s second-largest market, as they seek to harness the country’s rapidly improving drug discovery capabilities and identify promising new treatment candidates.

Source link